FULC logo

FULC
Fulcrum Therapeutics Inc

2,303
Mkt Cap
$526.14M
Volume
600,696.00
52W High
$15.74
52W Low
$2.54
PE Ratio
-6.70
FULC Fundamentals
Price
$7.91
Prev Close
$7.90
Open
$7.83
50D MA
$8.72
Beta
1.33
Avg. Volume
1.38M
EPS (Annual)
-$1.18
P/B
1.51
Rev/Employee
$0.00
$370.68
Loading...
Loading...
News
all
press releases
Aberdeen Group plc Has $14.18 Million Stock Holdings in Fulcrum Therapeutics, Inc. $FULC
Aberdeen Group plc raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 809.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Brokerages
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and sev...
MarketBeat·6d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Sees Strong Trading Volume - Still a Buy?
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase - Still a Buy...
MarketBeat·9d ago
News Placeholder
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk
Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physician interest and encouraging clinical signals from the company's PIONEER study in sickle cell disease...
MarketBeat·24d ago
News Placeholder
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling...
MarketBeat·24d ago
News Placeholder
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
Boothbay Fund Management LLC raised its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 104.2% during the third quarter, according to its most recent disclosure with the...
MarketBeat·25d ago
News Placeholder
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP
Braidwell LP acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 219,488...
MarketBeat·26d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5% - Here's Why
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 7.5% - Here's Why...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued...
MarketBeat·1mo ago
News Placeholder
Equities Analysts Issue Forecasts for FULC FY2030 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Fulcrum Therapeutics in a note issued to investors on...
MarketBeat·1mo ago
<
1
2
...
>

Latest FULC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.